Furthermore, the inhibitory effects were more pronounced in NIS-expressing thyroid cancer (K1-NIS), which is estimated to be sensitive to 131I. In vitro and in vivo experiments on synergistic treatment effects by combined therapy suggested that it might be most effective for RAI-avid thyroid cancer, which retains NIS function. Here, SLC5A5 is linked to thyroid cancer.